1. Introduction {#sec0005}
===============

Caliciviruses are non-enveloped, single-stranded RNA viruses of positive-sense polarity. Their genomes range from 7.3 to 8.3 kb in size, and these viruses have a diameter between 27 and 40 nm ([@bib0020]). They are divided into five genera: *Vesivirus*, *Lagovirus*, *Norovirus*, *Sapovirus*, and *Nebovirus* ([@bib0015]). Phylogenetically, noroviruses (NoVs) are further classified into five genogroups (GI--V). GI, GII and GIV NoVs infect humans ([@bib0050]), whereas animal NoVs are mainly classified as GII (swine), GIII (ruminants), GIV (lions and dogs) and GV (mice) ([@bib0095]).

Bovine NoVs (BoNoVs) comprise two distinct genotypes: GIII.1 (prototype Bo/Jena/80/DE) and GIII.2 (prototype Bo/Newbury-2/76/UK). They were initially identified in fecal samples from diarrheic calves in England (Newbury-2) and Germany (Jena) in 1978 and 1980, respectively ([@bib0025], [@bib0125]). In the US, three bovine enteric calicivirus strains have been reported: NoV GIII.2 (Bo/CV186-OH/00/US) in Ohio ([@bib0100]), nebovirus (Bo/NB/80/US) in Nebraska ([@bib0100]), and NoV GIII.1 in Michigan and Wisconsin ([@bib0115]). The economic impact of BoNoVs in the beef or dairy cattle industry is unclear. Previous virologic and serologic surveillance studies report frequent detection of BoNoVs in stool samples of diarrheic calves and high seroprevalence in adult cattle ([@bib0055], [@bib0075], [@bib0100]), implying a role for BoNoVs as a causative agent of calf diarrhea. The aim of our study was to characterize the pathogenesis of the GIII.2 BoNoV, CV186-OH strain in gnotobiotic (Gn) calves.

2. Materials and methods {#sec0010}
========================

2.1. Virus {#sec0015}
----------

The Bo/GIII.2/CV186-OH/00/US strain (GenBank accession no. AF542084) was detected from stool samples of a diarrheic Ohio veal calf ([@bib0100]). The strain was subsequently shown to cause diarrhea and fecal shedding during each of 2 serial passages in Gn calves ([@bib0045], [@bib0100]).

2.2. Gnotobiotic calves and experimental calf infection {#sec0020}
-------------------------------------------------------

Near-term Angus × Jersey crossbred Gn calves were delivered aseptically by Cesarean section ([@bib0045]). Nine 4 to 7-day-old calves were randomly assigned to two groups: BoNoV infection (*n*  = 7; calves \#1--7) and Mock (*n*  = 2; calves \#8 and 9). Calves \#1 and 2 were inoculated orally with 11.9 log~10~  GE of the CV186-OH strain, while calves \#3--7 were inoculated orally with lower doses of the calf \#1-passaged intestinal contents as follows: 11.0--11.3 log~10~  GE (calves \#3--5) and 10.0--10.1 log~10~  GE (calves \#6 and 7). After BoNoV inoculation, we monitored clinical signs daily until necropsy. Degree of lethargy was evaluated by the magnitude of loss of appetite and activity of calves. Diarrhea was assessed by scoring fecal consistency. Fecal consistency was scored as follows: 0, solid; 1, pasty; 2, semi-liquid; 3, liquid, with scores of 1 or more considered diarrheic. Scores 1--3 indicate mild to severe diarrhea, respectively. Calves \#3 and 4 were monitored for longer-term clinical signs and virus shedding until PID 30 and PID 21, respectively. Other infected or negative calves were kept for shorter-term studies and were euthanized for histopathological and serological examination at an acute-stage (PIDs 1--3), a mid-stage (PIDs 4--6), and a later-stage (PIDs 8--30) of BoNoV infection. The Institutional Animal Care and Use Committee (IACUC) of The Ohio State University approved all protocols related to the animal experiments in this study. All animals used in this study were also handled in accordance with the guidelines of the IACUC of the Ohio State University.

2.3. Analysis of BoNoV fecal shedding titers {#sec0025}
--------------------------------------------

Fecal samples or rectal swabs were collected daily from each animal throughout the experiment. Fecal samples were diluted 1:10 in MEM (Invitrogen, Carlsbad, CA, USA), or two rectal swabs were suspended in 4 ml MEM. The RNA was extracted from 200 μl of centrifuged (2000 ×  *g* for 30 min at 4 °C) fecal suspensions using the RNeasy Minikit (Qiagen, Inc., Valencia, CA, USA) according to the manufacturer\'s instructions. The BoNoV fecal shedding titers were determined by TaqMan real-time RT-PCR (qRT-PCR) using the Qiagen OneStep RT-PCR kit with the forward primer SWGIIInewF (5′-CGCTCYATGTTYGCWTGG-3′), reverse primer SWGIIIrev (5′-TCAGTCATCTTCATTTACAAAATC-3′), and probe SWGIIIprobe (FAM-TGTGGGAAGGTAGTCGCGACRYC-BHQ) targeting the junction region between ORF1 and ORF2 ([@bib0120]). Reverse transcription was conducted at 50 °C for 30 min, followed by a 15 min denaturation step at 95 °C and 45 cycles of 95 °C for 15 s and 60 °C for 1 min using an Eppendorf Realplex thermocycler (Eppendorf, Germany). A standard curve was generated using a plasmid DNA carrying the CBECU F/R amplicon of the Bo/GIII.2/CV186-OH/00/US strain ([@bib0100]). The detection limit was 10 genomic equivalents (GE) per 20-μl reaction (cycle threshold 35.23), corresponding to 3.7 log~10~ and 2.7 log~10~  GE per ml in fecal and serum samples, respectively.

2.4. Serum antibody detection ELISA {#sec0030}
-----------------------------------

A recombinant baculovirus containing the capsid protein (VP1) gene (ORF2) of CV186-OH/00/US strain was generated previously by using the Bac-N-Blue Transfection kit (Invitrogen, Carlsbad, CA, USA) ([@bib0040]). For comparison, the VLPs of Hu/GII.4/HS194/2009/US NoV were also tested in this ELISA ([@bib0065]). The CV186-OH/00/US and Hu/NoV/GII.4/HS194/2009/US VLPs, semi-purified by ultracentrifugation through a 40% (w/v) sucrose cushion, were used as antigens in a standardized antibody capture ELISA, as validated previously ([@bib0110]). Briefly, 96-well microtiter plates (Nalgene Nunc, Rochester, NY, USA) were coated overnight at 4 °C with 1 μg/ml of either CV186-OH/00/US or Hu/NoV/GII.4/HS194/2009/US VLPs or with semi-purified Sf9 cell supernatant as negative control in 0.01 M phosphate buffered saline (PBS) (pH 7.4). Blocking was performed with one of the 2 following blocking solutions: i) Blocking solution A, 2% non-fat dry milk (NFDM) in 0.01 M PBS-T (pH 7.4), containing 0.05% Tween-20; and ii) Blocking solution B, 1× buffered solution of casein (10× Power Block™ Universal Blocking Reagent, Biogenx, CA, USA) in distilled water for 2 h at room temperature (RT). Four-fold serial dilutions, beginning at 1:4, of the bovine paired serum samples were added to wells, and the plates were incubated for 1.5 h at Rt. A goat polyclonal antibody to bovine IgG (whole IgG) and conjugated to horseradish peroxidase (KPL, Gaithersburg, MD, USA) was diluted (1:1000) in 0.01 M PBS-T (pH 7.4). The plates were incubated for 1.5 h at RT. The assay samples were developed with tetramethylbenzidine (KPL), incubated for 15--20 min at Rt, and stopped with 1.8 N H~2~SO~4.~ The absorbance at 450 nm was measured by using an *E* ~max~ microplate reader (Molecular Devises Co., Sunnyvale, CA, USA). Paired positive and negative wells with a resulting difference in absorbance greater than the cut-off value (average value for absorbance of negative control samples plus 3 times the standard deviation) were considered positive for CV186-OH/00/US or HS194/2009/US NoV antibodies. The antibody titers were calculated and expressed as the reciprocal of the highest serum dilution positive for CV186-OH/00/US or HS194/2009/US NoV IgG antibodies.

2.5. Histological analysis and immunohistochemistry/*in situ* hybridization {#sec0035}
---------------------------------------------------------------------------

Small (duodenum to ileum) and large (cecum and colon) intestinal tissues and other major organs (lung, liver, heart, kidney, spleen, and lymph node) were examined grossly and histologically and tested by immunohistochemistry (IHC)/*in situ* hybridization (ISH) for BoNoV antigen/RNA detection. Tissues were fixed in 10% neutral formalin for 2 days at RT, and frozen tissues were also prepared in Tissue-Tek OCT compound (Sakura, Torrance, CA, USA) shortly after necropsy. The tissue slides were stained with Mayer\'s hematoxylin and eosin for light microscopy examination. Tissues from two age-matched mock controls were tested for histological comparisons and as a negative control for IHC/ISH. IHC was performed on formalin-fixed, paraffin-embedded tissues or fresh frozen tissues, as described previously ([@bib0065]), using the hyperimmune Gn calf antiserum ([@bib0045], [@bib0035]), a convalescent Gn calf serum against the CV186-OH strain, or a guinea pig hyperimmune antiserum against VLPs of the CV186-OH strain ([@bib0045], [@bib0035]). For BoNoV RNA detection in tissues, a non-radioactive digoxigenin labeled cDNA probe targeting the 480-bp virus-specific RNA-dependent RNA polymerase (RdRp) gene sequence amplified with the CBECU-F/R primer set was created and applied to ISH, as previously described ([@bib0060], [@bib0100]).

3. Results {#sec0040}
==========

3.1. Clinical observations {#sec0045}
--------------------------

Most of the infected Gn calves exhibited acute, intermittent but persisting diarrhea, accompanied by acute lethargy. Regardless of the different inoculum doses and use of an additional calf-passaged inoculum (calves \#3--7), six of 7 infected calves (85.7%) commonly exhibited the following clinical signs: (i) acute onset of mild to moderate diarrhea that persisted through PID 20 or PID 26 (calves \#3 and 4) ([Fig. 1](#fig0005){ref-type="fig"} ); and (ii) acute moderate to severe lethargy that was observed only at PID 1. However, the lethargy subsided or disappeared at later PIDs. Diarrheic feces were loose or occasionally appeared watery and yellow or yellow-green in color, and the amount was noticeably increased compared to control calves. No negative control calves showed diarrhea and other clinical signs, such as lethargy, throughout the experiment. Because of the clinical aspects similar to other bovine enteric viruses, such as rotavirus or coronavirus, further EM examination was conducted to confirm whether only NoV particles were present in the calf-passaged fecal samples. The tests showed no contamination of Gn calf-passaged diarrheic fecal samples with other detectable enteric viruses or bacteria.Fig. 1Intermittent but persisting diarrhea and prolonged fecal viral RNA shedding of calves \#3 and 4 infected with GIII.2 BoNoV, CV186-OH strain. Calves \#3 and 4 were inoculated orally with lower doses (11.0--11.3 log~10~ GE) of the calf \#1-passaged intestinal contents. They were monitored for longer-term clinical signs and virus shedding for PIDs 1--30 and PIDs 1--21, respectively. Fecal samples or rectal swabs were collected daily from each animal throughout the experiment. The BoNoV fecal shedding titers were determined by qRT-PCR, and each test was performed in triplicate. The dotted line indicates the detection limit (3.7 log~10~ GE/ml) of the qRT-PCR.

3.2. BoNoV RNA fecal shedding {#sec0050}
-----------------------------

Viral RNA in fecal samples was first detected at PID 1 (5/7; 71%) or PID 2 (2/7; 29%) ([Table 1](#tbl0005){ref-type="table"} ). Regardless of the different inoculum doses and existence of an additional calf-passage among the inocula used, peak fecal viral RNA were mostly observed at PID 1 (calves \#2--4 and 6) but occasionally at later PIDs (≥PID 3) (calves \#1 and 7) ([Table 1](#tbl0005){ref-type="table"}). Calves \#3 and 4, followed longer-term, had prolonged viral RNA shedding until PID 30 and PID 20, respectively ([Fig. 1](#fig0005){ref-type="fig"}). Fecal viral RNA titers in both calves peaked at PID 1 and decreased progressively thereafter ([Fig. 1](#fig0005){ref-type="fig"}). No negative control calves shed detectable viral RNA in the feces throughout the experiment.Table 1Virus RNA shedding determined by qRT-PCR in the feces of GIII.2 BoNoV (CV186-OH)-infected calves during the early stages of infection.Calf \#Calf age when inoculatedInoculum titer (log~10~ GE/calf)Viral titers (log~10~ GE/ml of rectal swab fluid or fecal sample)PID when virus titer peakedPost-inoculation day (PID)(day)01234561611.9\<3.7[a](#tblfn0005){ref-type="table-fn"}\<3.79.9[b](#tblfn0010){ref-type="table-fn"}10.6EU[c](#tblfn0015){ref-type="table-fn"}≥3 (ND[d](#tblfn0020){ref-type="table-fn"})2511.9\<3.710.19.7EU13[e](#tblfn0025){ref-type="table-fn"}411.3\<3.711.911.910.911.210.910.41 and 24[e](#tblfn0025){ref-type="table-fn"}411.0\<3.711.610.310.110.19.68.915411.0\<3.711.4 (EU)≥1 (ND)6710.0\<3.710.710.110.48.78.8EU17710.1\<3.7\<3.710.410.710.9EU≥4 (ND)[^1][^2][^3][^4][^5]

3.3. BoNoV RNA detection in serum {#sec0055}
---------------------------------

By qRT-PCR, 5 infected calves (\#1--3, 5, and 7) tested acutely (PIDs 1--5) had low viral RNA titers in serum, ranging from 4.0 to 5.8 log~10~  GE/ml, but not (\<2.7 log~10~  GE/ml) in the samples tested thereafter (PIDs 6--30) ([Table 2](#tbl0010){ref-type="table"} ). The latter observation coincided with the presence of serum IgG antibody to BoNoV at PIDs 8--30 ([Table 2](#tbl0010){ref-type="table"}). No infected calves or negative controls had detectable viral RNA in the prebled serum samples prior to inoculation or during the experiment, respectively.Table 2Detection of viral RNA by qRT-PCR and IgG antibody titers to BoNoV in serum samples.Calf \#PID (or age of negative control calf)qRT-PCR results[a](#tblfn0030){ref-type="table-fn"}Serum IgG antibody titersVLPs of GIII.2 BoNoV (CV186-OH)VLPs of GII.4 HuNoV (HS194)ELISA blocking solution A[b](#tblfn0035){ref-type="table-fn"}ELISA blocking solution B[b](#tblfn0035){ref-type="table-fn"}ELISA blocking solution AELISA blocking solution B*Infected*10−(\<2.7)\<4\<4\<4\<44+(4.1)\<4\<4\<4\<4  20−(\<2.7)\<4\<4\<4\<43+(4.0)\<4\<4\<4\<4  30−(\<2.7)\<4\<4\<4\<42+(4.1)\<4\<4\<4\<49−(\<2.7)\<41024\<4\<430−(\<2.7)2564096\<4256  40−(\<2.7)\<4\<4\<4\<48−(\<2.7)\<4256\<4\<421−(\<2.7)2564096\<464  50−(\<2.7)\<4\<4\<4\<41+(5.8)\<4\<4\<4\<4  60−(\<2.7)\<4\<4\<4\<46−(\<2.7)\<4\<4\<4\<4  70−(\<2.7)\<4\<4\<4\<41−(\<2.7)\<4\<4\<4\<45+(5.5)\<4\<4\<4\<4  *Uninfected*813−(\<2.7)\<4\<4\<4\<498−(\<2.7)\<4\<4\<4\<4[^6][^7]

3.4. Serum IgG antibody response to BoNoV {#sec0060}
-----------------------------------------

Serum IgG antibody detection was performed by Bo/GIII.2/CV186-OH/00/US VLP-based ELISA. The VLPs of a GII.4 human NoV (HS194/2009/US) were also tested in ELISA ([@bib0065]). Calves \#3 and 4, followed longer-term, had serum antibodies against GIII.2 BoNoV at PID 21 and PID 30, respectively, indicating seroconversion of both calves. The serum samples positive for BoNoV-specific antibodies at PIDs 21 and 30 also showed cross-reactivity to VLPs of the GII.4 human NoV strain HS194 when casein (solution B) was used as a blocking solution ([Table 2](#tbl0010){ref-type="table"}). The results concur with several prior studies, reporting presence of potential cross-reactive antigenic epitope(s) in the capsid protein of GIII.2 BoNoVs and GII.3/GII.4 human NoVs ([@bib0070], [@bib0080]). Substitution of casein (solution B) for 2% NFDM (solution A) blocking greatly increased assay sensitivity, which also led to seropositivity at the mid-stage of infection (PIDs 8 and 9).

3.5. Histopathology and IHC/ISH {#sec0065}
-------------------------------

Light microscopic examination revealed that none of the infected calves had major histological changes in the intestine, such as necrosis of intestinal epithelium, villous atrophy, or inflammatory lesions, although all of them exhibited diarrhea or fecal virus shedding. By IHC/ISH, concurrently, no BoNoV antigen/RNA-positive cells were observed in small and large intestinal tissues and other organs of the CV186-OH-infected Gn calves.

4. Discussion {#sec0070}
=============

Our current study demonstrates persisting diarrhea and prolonged fecal shedding, but with a lack of significant acute intestinal lesions, in Gn calves infected with the BoNoV GIII.2 strain CV186-OH/00/US. The enteropathogenic characteristics of the CV186-OH/00/US virus differs from that of the Jena GIII.1 BoNoV, but resembles the persistent diarrhea or prolonged fecal shedding of human GII NoVs in children or immunocompromised patients.

The pathogenicity of the nebovirus Newbury-1 appeared more severe than the GIII.2 BoNoV strain Newbury-2 ([@bib0010], [@bib0030]). The Gn calves infected with Newbury-1 nebovirus exhibited anorexia and maladsorptive diarrhea, and they also had intestinal lesions, such as atrophic jejunitis, in which IHC-positive cells were identified using convalescent antiserum to detect viral antigens ([@bib0010], [@bib0030]). Our lab reported that the GIII.2 BoNoV, CV186-OH strain induced diarrhea, fecal virus shedding (RT-PCR), and seroconversion in infected Gn calves ([@bib0045], [@bib0035]), but no histopathology or IHC studies were conducted on the infected calves. A recent study reported prolonged shedding, as determined by qRT-PCR, of conventional calves experimentally infected with a Norwegian GIII.2 BoNoV strain ([@bib0055]). For GIII.1 BoNoV, conventional calves infected with the Jena strain showed early, short-term shedding (RT-PCR and ELISA) (≤PID 4) and diarrhea (≤PID 3), but they all had severe atrophic enteritis ([@bib0085]). Our study demonstrated that, unlike the Jena GIII.1 BoNoV, the CV186-OH GIII.2 BoNoV did not induce any major histological changes in the intestine of Gn calves, such as necrosis of intestinal epithelium, villous atrophy, or inflammatory lesions. Viral antigens/RNA were not detected in the intestine by IHC/ISH, indicating difficulties with *in situ* identification of this virus using routine pathology techniques, and thus requiring improved detection (IHC/ISH) methods with increased sensitivity. Thus, persisting diarrhea exhibited by the infected calves might not be related to virus-induced changes in the intestine as determined by histologic examination, but might be associated with virus-induced immunopathology or possible structural and functional alterations in the intestinal epithelium. Further studies are needed to elucidate the disease mechanisms related to GIII.2 BoNoV infection.

In our study, the CV186-OH strain induced acute, intermittent but persisting diarrhea in 4 to 7-day-old immunocompetent Gn calves. Similar to persisting diarrhea seen in CV186-OH virus infection, immunocompromised humans with GII NoV infections exhibited persistent diarrhea lasting for an average of 8 months ([@bib0090]). Another similar aspect between the GIII.2 BoNoV and GII human NoVs includes detection of NoV RNA in the sera of immunocompetent NoV-infected children ([@bib0105]) or young Gn calves, as revealed in our study. Distinct from the GIII.2 BoNoV and human NoVs, the Jena GIII.1 BoNoV induced only a short-term diarrhea for 2 or 3 days after inoculation in neonatal colostrum-deprived, immunocompetent conventional calves ([@bib0085]).

Our study demonstrates that CV186-OH-infected Gn calves had prolonged fecal viral RNA shedding, at least until PID 20. Our findings concur with a prior study, showing that two colostrum-fed, conventional calves infected with a Norwegian GIII.2 BoNoV strain exhibited prolonged fecal viral RNA shedding lasting for PIDs 1--23 or 1--32 ([@bib0055]). Likewise, volunteer studies using healthy adults revealed prolonged viral RNA shedding with a median time of 28 days (range 13--56 days) after experimental inoculation with human NoV (GI.1) ([@bib0005]). Also, in immunocompromised humans with GII NoV infections, prolonged viral RNA shedding with a median time of 289 days (range 107--581 days) was detected ([@bib0090]). Unlike the GIII.2 BoNoV and human NoVs, the Jena GIII.1 BoNoV induced only short-term virus shedding for PIDs 0.5--4 in neonatal colostrum-deprived, immunocompetent conventional calves ([@bib0085]).

The sera of calves \#3 and 4 were positive for BoNoV antibodies at PIDs 21 and 30, which also showed cross-reactivity with VLPs of GII.4 human NoV strain HS194. These two bovine and human NoVs appear to share antigenic epitope(s) in the capsid protein, as suggested in several previous studies ([@bib0070], [@bib0080]). A cross-reactive epitope between GIII.1/GIII.2 BoNoVs and GII.3 HuNoVs was also identified ([@bib0080]), and an epitope site (N2C3) in the capsid protein of GII.4 HuNoV was reported to be shared with GIII.1/GIII.2 BoNoVs and murine NoVs (GV) ([@bib0070]).

In conclusion, CV186-OH GIII.2 BoNoV infection led to persisting diarrhea and prolonged fecal shedding, but with no significant intestinal lesions, in infected Gn calves. The enteropathogenic characteristics of the virus differed from the short-term diarrhea and fecal virus shedding that the Jena GIII.1 BoNoV induced in conventional calves, with remarkably severe atrophic jejunitis, suggesting milder enteropathogenicity of the CV186-OH GIII.2 BoNoV. Nevertheless, persisting diarrhea and prolonged fecal virus shedding that GIII.2 BoNoV induces, as confirmed in young Gn calves in our study, might contribute to establishment of an endemic situation of enteric disease in young cattle from dairies, feedlots and veal farms. In addition, our data suggest that enteric infection of Gn calves with GIII.2 BoNoV, CV186-OH strain is a useful model for comparative pathogenesis studies of other enteric NoV infections, such as human NoV, due to the pathogenic similarities (prolonged shedding) between GIII.2 BoNoV and human NoVs, as identified in our study. This model might also help to elucidate the role of innate and adaptive immunity in the clearance of NoV from the infected intestine or prolonged virus shedding and diarrhea.
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[^1]: Real-time PCR-negative, \<3.7 log~10~ GE/ml (detection limit of the qRT-PCR for rectal swab fluid or fecal sample).

[^2]: Real-time PCR-positive, log~10~ viral titer (GE/ml of rectal swab fluid or fecal sample).

[^3]: EU, euthanized.

[^4]: ND, not determined.

[^5]: Virus shedding of calves \#3 and 4 monitored for longer-term ([Fig. 1](#fig0005){ref-type="fig"}).

[^6]: +/−, real-time PCR-positive (viral RNA titers; log~10~ GE per serum sample) or negative (\<2.7 log~10~ GE/ml; detection limit of the qRT-PCR for serum sample).

[^7]: ELISA blocking solution A; 2% non-fat dry milk (NFDM), ELISA blocking solution B; 1× buffered solution of casein (Universal Blocking Reagent, Biogenex, CA).
